Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28308740 | 0.87 | APP (0.61) | APPKCNH2FFAR1L3MBTL1TDP1 | |
| SCHEMBL1920649 | 0.85 | CYP1A2 (0.49) | APPKCNH2FFAR1L3MBTL1MAPT | |
| SCHEMBL10412693 | 0.80 | FFAR1 (0.60) | APPKCNH2FFAR1L3MBTL1ACACB | |
| SCHEMBL28353258 | 0.80 | APP (0.58) | APPKCNH2FFAR1L3MBTL1MAPT | |
| SCHEMBL1921687 | 0.79 | ACACB (0.53) | APPKCNH2FFAR1L3MBTL1ACACB | |
| SCHEMBL1923029 | 0.79 | ACACB (0.52) | APPKCNH2FFAR1L3MBTL1MAPT | |
| SCHEMBL28520315 | 0.79 | APP (0.52) | APPKCNH2FFAR1L3MBTL1TDP1 | |
| SCHEMBL29120782 | 0.79 | APP (0.52) | APPKCNH2FFAR1L3MBTL1TDP1 | |
| SCHEMBL28368555 | 0.79 | POLB (0.57) | APPKCNH2FFAR1L3MBTL1MAPT | |
| SCHEMBL28296194 | 0.79 | ALDH1A1 (0.63) | APPKCNH2FFAR1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| EP-2170833-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009000411-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | APP 4673/4885KCNH2 41/4885FFAR1 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.